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We read with great interest the recently published
article by Törlén et al., in which the authors analyzed a
large population of patients with acute myeloid leukemia
and myelodysplastic syndrome who underwent reduced-
intensity conditioning (RIC) allogeneic hematopoietic cell
transplantation. The authors found that a peripheral blood
progenitor cell (PBPC) CD34þ dose > 4  106 CD34þ/kg and
> 6  106 CD34þ/kg was associated with lower mortality
in HLA-matched sibling and unrelated donor hematopoi-
etic cell transplantation, respectively, in the setting of RIC.
The authors concluded that their data offer the opportu-
nity to establish standards for PBPC collection [1]. How-
ever, we believe that the eligibility criteria in this paper
fail to explain whether the CD34þ dose estimation was
based on the actual body weight, ideal body weight (IBW),
or adjusted ideal body weight (AIBW) of the patients. In
this study, obese patients represented 28.4% of the overall
population. An estimation based on actual weight may
explain why there were more obese patients in the group
of CD34þ low dose and related donor, and why body mass
index did not affect mortality. There are data suggesting
that IBW and/or AIBW may be a better basis for calculatingFinancial disclosure: See Acknowledgments on page 196.
* Correspondence and reprint requests: Ana Lisa Basquiera, MD, Hema-
tology and Oncology Service, Hospital Privado Centro Médico de Córdoba,
Naciones Unidas 346 (5016), Córdoba, Argentina.
E-mail address: abasquiera@hospitalprivadosa.com.ar (A.L. Basquiera)
1083-8791/$ e see front matter  2015 American Society for Blood and
Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.2014.09.018cell dose in autologous and allogeneic transplantation
settings [2-6]. Both IBW- and AIBW-based calculations of
CD34þ cells infused were better predictors of neutrophil
recovery in comparison to actual body weight after
allografting [2]. After RIC allogeneic transplantation,
CD34þ and CD3þ cell doses based upon IBW were found to
signiﬁcantly affect transplantation-related mortality and
disease-free and overall survival [3]. Also, individuals who
donate PBPC for overweight patients may undergo an
unnecessary higher demand from apheresis procedures
[3]. Thus, we believe this may be an important aspect to
consider at the moment of establishing standards for PBPC
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